<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Hepatocellular Carcinoma
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/hepatocellular-carcinoma" data-history-node-id="946" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <table class="TableGrid8" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Hepatocellular Carcinoma (HCC) â€“ Julie Cui</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Background
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pts with HCV cirrhosis are at greatest risk (incidence 2-4% per year)
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                In chronic HBV, pts can develop HCC without having cirrhosis, as can patients with NASH
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Evaluation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Regular screening in pts w/ cirrhosis HCC
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Also recommended to screen non-cirrhotic with chronic HBV
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  U/S every 6 months (w/ or w/o AFP)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Routine screening with CT or MRI is not recommended
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Options If U/S not satisfactory:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  CT A/P w/contrast, in comments specify triple phase for HCC screening
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  MRI, specify Gadovist (preferred contrast agent)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Contrast-enhanced ultrasound
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                AFP trend is more useful than 1 value in time
                <b>
                 ,
                </b>
                though AFP >20 should prompt multiphase CT or MRI for further evaluation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Diagnosis can be made either by imaging (most common) or biopsy (rarely).
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Triple phase CT demonstrates strong early uptake in arterial phase, with subsequent wash-out in portal-venous phase
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  If diagnosis remains unclear: can surveillance imaging or biopsy
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  LI-RADS system notes risk of malignancy based on imaging characteristics
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
        </ul>
        <p style="margin-left:37px">
        </p>
        <table class="Table" style="width:100.0%; border-collapse:collapse" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LI-RADS</td>
      <td>What does it mean?</td>
      <td>What do we do?</td>
    </tr>
    <tr>
      <td>LR-1 to LR-2</td>
      <td>Definitely/Probably benign</td>
      <td>Routine surveillance, consider diagnostic imaging within 6 mos</td>
    </tr>
    <tr>
      <td>LR-3 to LR-4</td>
      <td>Indeterminate/Probably HCC</td>
      <td>Repeat or alternative diagnostic imaging in 3-6 mos. Consider Bx for LI-RADS 4</td>
    </tr>
    <tr>
      <td>LR-5</td>
      <td>Definitely HCC</td>
      <td>Plan treatment as noted below</td>
    </tr>
    <tr>
      <td>LR-M</td>
      <td>Cancer but may not be HCC</td>
      <td>NaN</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
         <br/>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Management
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Lesions that meet Milan criteria can qualify for MELD exception points and are considered transplant candidates
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  This accounts for pts w/minimal synthetic dysfunction (and therefore low MELD)
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Milan criteria:
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Single tumor with diameter >2cm but <5 cm, no more than 3 tumors, each <3 cm
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  No signs of extra-hepatic involvement or vascular invasion
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Pts may remain transplant candidates if rx downstages their HCC to meet above criteria
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Liver transplant is definitive treatment, although
                <b>
                 resection
                </b>
                can also be curative
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="font-family:Calibri,sans-serif">
                <span style="font-size:12.0pt">
                 <span style="font-family:Palatino">
                  Favored in pts w/early cirrhosis (Child Pugh A) and HCC amenable to resection
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                Locoregional therapies: Pts w/ unresectable disease, or who are not surgical candidates
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <table class="TableGrid8" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Therapy</td>
      <td>Details</td>
    </tr>
    <tr>
      <td>Radiofrequency ablation</td>
      <td>If in a favorable location and size, IR can percutaneously ablate with a large needle that emits microwave frequencies</td>
    </tr>
    <tr>
      <td>Trans-arterial chemoembolization (TACE)</td>
      <td>Chemotherapeutic agents injected into the tumor to occlude the feeding blood supply to the area.</td>
    </tr>
    <tr>
      <td>Trans-arterial radioembolization (TARE)</td>
      <td>Like TACE, though radioactive compound (i.e. Y-90) used to occlude the feeding blood supply.</td>
    </tr>
    <tr>
      <td>Stereotactic body Radiation Therapy (SBRT)</td>
      <td>Radiation therapy: can be used as an alternative to ablation and is generally performed in those meeting Milan criteria</td>
    </tr>
    <tr>
      <td>Systemic Chemotherapy</td>
      <td>For metastatic disease</td>
    </tr>
  </tbody>
</table>
        </table>
       </div>
       <p>
       </p>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>